Completed PHASE1 INTERVENTIONAL 2-arm NCT04714229

Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135 and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Sponsor: EuBiologics Co.,Ltd

Conditions Infection, Meningococcal

Interventions Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine

Updated 5 times since 2021 Last updated: Oct 6, 2021 Started: Sep 1, 2020 Primary completion: Nov 1, 2020 Completion: Sep 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04714229, this PHASE1 trial focuses on Infection, Meningococcal and remains completed. Sponsored by EuBiologics Co.,Ltd, it has been updated 5 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Feb 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE1

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EuBiologics Co.,Ltd

Data source: EuBiologics Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea